Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

ng a child. In addition, women treated with Vidaza should not nurse.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase 2 monotherapy and Phase 1 and Phase 2 combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to the planned development program for MGCD0103, which express the current beliefs and expectations of management. Such statements are based on current expectations and invol
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 ... für kongestive Herzinsuffizienz (CHF) in seiner ersten ...     Die israelische ... Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz (CHF) ... ein Finanzierungsvorhaben über 5 Mio. USD abgeschlossen ...
(Date:2/27/2015)... Feb. 27, 2015  Two mass spectrometry ... applications as their effectiveness is established, according ...  Kalorama Information says that while mass spectrometry ... powerful tool in proteomic biomarker discovery and ... its traditional techniques has struggled to elucidate ...
(Date:2/26/2015)... , Feb. 26, 2015  AbbVie (NYSE: ... of studies in its neuroscience and oncology development ... 67 th American Academy of Neurology annual ... from April 18-25. The accepted abstracts feature results ... addition to investigational treatments in AbbVie,s pipeline. Presentations ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), ... a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence ... Database," at Digestive Disease Week, on May 31, 2009. ... continuing patients, 20 percent of Lialda patients were continually ...
... Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ... 1 safety and efficacy results following administration of ... with high-risk genomic factors and relapsed or refractory ... proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate. ...
Cached Medicine Technology:Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 2Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 3Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 4Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 5Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 2Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 3Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 4Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 5
(Date:2/27/2015)... Pipette.com announces their limited time pricing ... only valid until the end of March 2015. The ... vortex mixer that allows for absolute control and true ... and is headquartered in Bohemia, New York. Scientific Industries ... as other rockers, incubators, and hybridization ovens which are ...
(Date:2/27/2015)... The V Foundation for Cancer Research, one ... excited to announce numerous promotions taking place this March. ... partnerships highlight The V Foundation’s significant work in the ... all to get involved. Awarding 100 percent of ... V Foundation has funded more than $130 million in ...
(Date:2/27/2015)... 2015 According to court documents, Donna ... June 25, 2013 and underwent a procedure during which ... mouth. Because the duodenoscope allegedly had not been ... “superbug” carbapenem-resistant Enterobacteriaceae (CRE). , A lawsuit ... County on behalf of Ms. Pirolli alleging that Lutheran ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 Winter is ... like on human skin, exposure to snow and ice can ... can also hurt dogs’ paws. The Puppy Store is ready ... to keep their dogs safe in the winter time. , ... causing vomiting, diarrhea and other symptoms. Ingestion of ice melt ...
(Date:2/27/2015)... 2015 FACE Skincare~Medical~Wellness, a multiaward-winning ... a unique combination to take fifteen years off ... is a new treatment introduced that is the ... indicated to improve lines and wrinkles on the ... who suffers from the stubborn vertical lines between ...
Breaking Medicine News(10 mins):Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:Face Skincare Announces New Combination Therapy 2
... , , ROANOKE, Va., July ... The Virginia Psychological Association (VPA) and Virginia ... approaches to curbing this cost by awarding the 2009 VPA/VACP ... the deadline to submit nominations. , ...
... , , , ... the introduction of the newly branded Eventone Glycolic Texturizer, formerly ... U.S., including select Walgreens, HEB and CVS stores. Eventone ... by dermatologist Milton D. Moore, MD, is a breakthrough formula ...
... SPOKANE, Wash., July 23 Inland Northwest ... hold the Northwest Medical Informatics Symposium (NMIS), a health ... September 10 and 11 in Spokane, Washington. NMIS ... about the latest in health information technology. Pre-Conference Workshops ...
... , INDIANAPOLIS, July 23 ... announced that the U.S. Food and Drug Administration (FDA) has ... (rDNA origin) injection] to treat osteoporosis associated with sustained, systemic ... fracture. Glucocorticoid therapy is the most common cause of secondary ...
... Technologies, Inc. (Nasdaq: PMTI ), a leading researcher ... its quarterly conference call of its 2009 second quarter financial ... Time. If you would like to participate, please call (866) ... telephone replay will be available one hour after the call ...
... 23 Bay Area Registered nurse-turned filmmaker, David Burton, dropped ... a movie to help save lives. After seeing so ... connection between America,s food ingredients (specifically hydrogenated oil) and the ... world what he found. The movie titled "inGREEDients" is already ...
Cached Medicine News:Health News:Moore Unique Skin Care Announces the Release of Eventone Glycolic Texturizer for Men and Women 2Health News:INHS Brings Health Information Technology Conference to Spokane 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6Health News:Palomar Medical Technologies To Host Second Quarter 2009 Financial Results Conference Call and Webcast on July 30, 2009 2Health News:Nurse Turned Filmmaker Makes Lifesaving Film 2
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... 7300 Real-Time PCR System gives you ... exceptional budget sensitivity. , , Four-color ... expression analysis, pathogen quantitation, SNP genotyping, ... controls , Powerful, versatile software ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... Pathogen Identification Device) is a specialty ... responders and other rough environments. This ... technology into a portable, impact resistant ... button" use of the R.A.P.I.D. System ...
Medicine Products: